




'Short cuts and long delays' –

To streamlined, accelerated Drug development

# Some Lessons learnt from COVID19 pandemic



- Essential medicines – stockpiling
- Pandemic preparedness
- Large scale collaborations between Govt and Industry
- Mission driven approach to investments
- Speed of global collaborations
- Racial / Ethnic disparity






# Mission Statement

We're on a mission...

*Collaborate and innovate for medicines*

**Covate Pharma PTE. LTD.**

# Therapeutic Indications




**CNS –  
dementia, Alzheimer’s  
disease, Insomnia**

**CVS –  
Hypertension**

**Oncology**

**Antivirals –  
pan coronavirus  
Antimicrobials**

# Covate Pharma Agile Business model :





Building team  
in-progress

# Covate Pharma PTE. LTD. , Singapore

*Collaborate and innovate for medicines*



**Ameet Ambarkhane; M Pharm, PHD**

Director & Principal

[ameet@covatepharma.com](mailto:ameet@covatepharma.com)

+65 81141971

## **rior Experience :**

Drug development in Global Pharma & small Biotech

R&D - Special task force set-up to reduce the time for NCE to clinic (first in Man studies)

- MS&T (Manufacturing science and technology)
  - Newly set-up group to address technical gap at manufacturing facilities
- Drug Device combination products
- Offering – CMC & Drug Development to add value for small/mid size Biotech and expedite the access of medicines to patients




October 2020

Confidential


# Back-up



# Case 1 : New Drug Development (Pro-drug, high dose & Poor Bioavailability challenges)



## Case 2 : Inhaled Drug - New drug development Respiratory disease indication



# Prior Experience of Drug device combination products



- Nasal spray :
- Multidose suspension based formulation

October 2020



- Inhaler :
- Multidose DPI, Dry Powder inhaler

Confidential



- Inhaler :
- Unit dose DPI, Dry Powder Capsule based formulation

# Why Outsourcing ? (Post – Covid19 Scenario)



**Innovative approaches**



**Enabling formulations**



**New Delivery technologies**



**Manufacturing capability**



**Resource Constraints**



**Specific competency needs**

# Strategic insights Drug Product supply strategy

